Regis Technologies Opens Pharmaceutical Manufacturing Center In Morton Grove, Illinois
08/21/2015
The company spent two years constructing the suite and preparing its team for the new potent compound capabilities. The PCS addition provides for small molecule cGMP manufacturing of potent compounds up to about one kilogram per batch. PCS targets small molecule oncologicals and linker payload projects for antibody drug conjugates.
According to company officials, Regis invested in this project to extend their custom cGMP offerings to the oncology market. The new PCS will also provide new avenues of career development for its staff.
Director of Business Development, Wayne Nowicki, said, “We see the PCS as an important asset to serve the growing oncology market as more companies look to advance their lead candidates into the clinic.”
Regis’ Manager of Process Engineering, Dragan Ristic, supervised the design and construction of the suite. Proper handling of potent compounds requires the use of specialized facilities that are carefully designed to minimize containment risks. Regis’ new PCS includes isolators, laminar flow hoods and local exhaust ventilation appropriate for potent compound handling, company officials said.
Most Read
-
-
The New Normal in the Automotive Supply Chain
2020 Auto/Aero Site Guide
-
Why are Foreign Trade Zones Making a Comeback?
Q3 2020
-
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Q1 2020
-
Infrastructure Investment as an Economic Stimulus Tool
Q3 2020
-
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
Q3 2019
-
The Next Recovery: Regional Leaders & Laggards
Q3 2020